A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B
{{output}}
Background: In 2022-2023, the US Food and Drug Administration approved 2 novel gene therapies, valoctocogene roxaparvovec and etranacogene dezaparavovec, for hemophilia A and B, respectively. These one-time-administered gene ther... ...
